{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:04:36Z","timestamp":1789535076174,"version":"build-2803163510"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Palmoplantar pustulosis (PPP) is a chronic relapsing inflammatory dermatosis characterized by recurrent sterile pustules on the palms and soles and often shows inadequate or unsustained responses to conventional systemic therapies and biologics. We report a 58-year-old woman with a 3-year history of refractory PPP. Before referral, oral prednisone and acitretin provided only transient disease control, with rapid relapse during dose tapering. Apremilast combined with topical halometasone cream and 308-nm excimer laser therapy failed to adequately control the plantar lesions. After referral, the patient declined cyclosporine and methotrexate because of concerns regarding potential systemic adverse effects. Baseline PPPASI and DLQI scores were 46.0 and 23, respectively. Secukinumab 300\u2005mg with topical halometasone reduced the scores to 22.0 and 18 by week 8, indicating a partial but clinically inadequate response. Clinically active plantar lesions persisted, and new intensely pruritic erythematous papules developed on the lower extremities, accompanied by peripheral eosinophilia (0.62\u2009\u00d7\u200910\u2079\/L) and elevated serum IgE (256 kIU\/L). Secukinumab and topical halometasone were discontinued at week 8, and abrocitinib was initiated at 100\u2005mg once daily. PPPASI decreased to 1.5 and 1.2 and DLQI to 8 and 3 at weeks 4 and 8, respectively. By week 8, the lower-extremity papules had markedly improved, and the eosinophil count and serum IgE had returned to their reference ranges. At week 16, disease control remained stable without treatment-related adverse events or laboratory abnormalities. This case suggests that abrocitinib may represent a potential treatment option for selected patients with refractory PPP who exhibit a partial but clinically inadequate response to secukinumab and concurrent clinical and laboratory changes suggestive of Th2-associated inflammation.<\/jats:p>","DOI":"10.3389\/fmed.2026.1913582","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:32:22Z","timestamp":1789533142000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Abrocitinib treatment for refractory palmoplantar pustulosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaoyan","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Dermatology, The Affiliated Hospital of Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chengdu Integrated TCM and Western Medicine Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdie","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Affiliated Hospital of Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Affiliated Hospital of Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiong","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Affiliated Hospital of Southwest Medical University","place":["Luzhou, China"]},{"name":"Department of Dermatology, Chengdu Integrated TCM and Western Medicine Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdermsci.2020.03.003","article-title":"Palmoplantar pustulosis: current understanding of disease definition and pathomechanism","volume":"98","author":"Murakami","year":"2020","journal-title":"J Dermatol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jdv.13846","article-title":"What do we know about palmoplantar pustulosis?","volume":"31","author":"Misiak-Galazka","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/1346-8138.15826","article-title":"Similarity and difference between palmoplantar pustulosis and pustular psoriasis","volume":"48","author":"Yamamoto","year":"2021","journal-title":"J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/PTT.S400402","article-title":"Palmoplantar pustulosis: a systematic review of risk factors and therapies","volume":"13","author":"Heidemeyer","year":"2023","journal-title":"Psoriasis (Auckl)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40257-024-00849-0","article-title":"Small-molecule inhibitors and biologics for palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and network meta-analysis","volume":"25","author":"Huang","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1007\/s12325-025-03122-w","article-title":"Biologic treatment adherence and persistence in patients with palmoplantar pustulosis: a real-world, claims-based study","volume":"42","author":"Feldman","year":"2025","journal-title":"Adv Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jaci.2024.05.015","article-title":"A genome-wide meta-analysis of palmoplantar pustulosis implicates TH2 responses and cigarette smoking in disease pathogenesis","volume":"154","author":"Hernandez-Cordero","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e193038","DOI":"10.1172\/jci.insight.193038","article-title":"Th17 cells with regulatory phenotype are the main IL-17F and IL-26 producers in palmoplantar pustulosis","volume":"10","author":"Do","year":"2025","journal-title":"JCI Insight"},{"key":"B9","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jaci.2022.04.027","article-title":"Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis","volume":"150","author":"McCluskey","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/ced.13689","article-title":"Interleukin (IL)-8 and IL-36\u03b3 but not IL-36Ra are related to acrosyringia in pustule formation associated with palmoplantar pustulosis","volume":"44","author":"Xiaoling","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2025-7-10","DOI":"10.7573\/dic.2025-7-10","article-title":"JAK Inhibitors for the treatment of palmoplantar pustulosis: a narrative review","volume":"22","author":"Henriques dos Santos","year":"2025","journal-title":"Drugs Context"},{"key":"B12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of JAK\u2013STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2594352","DOI":"10.1080\/07853890.2025.2594352","article-title":"Targeting the JAK\/STAT pathway in palmoplantar pustulosis: a review","volume":"57","author":"Chirindo","year":"2025","journal-title":"Ann Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s40257-025-00971-7","article-title":"Upadacitinib versus Acitretin for the resolution of pustules in palmoplantar pustulosis during acute phase: a single-center, open-label prospective cohort study","volume":"26","author":"Huang","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1476793","DOI":"10.3389\/fmed.2024.1476793","article-title":"Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients","volume":"11","author":"Du","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2280508","DOI":"10.1080\/09546634.2023.2280508","article-title":"Palmoplantar pustulosis with psoriatic arthritis ineffective to interleukin-17 inhibitors: two patients successfully treated with upadacitinib","volume":"34","author":"Zhang","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.06.092","article-title":"Ivarmacitinib is associated with rapid clinical improvement and immune remodeling in palmoplantar pustulosis: a multicenter, single-arm clinical trial","author":"Xu","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/1346-8138.17702","article-title":"Disease features, treatments, and burden of palmoplantar pustulosis in Korea: the EPPPIK study","volume":"52","author":"Jo","year":"2025","journal-title":"J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40257-023-00788-2","article-title":"Efficacy and safety of apremilast for the treatment of Japanese patients with palmoplantar pustulosis: results from a phase 2, randomized, placebo-controlled study","volume":"24","author":"Terui","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal"},{"key":"B22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/ddg.70238x","article-title":"Palmoplantar pustulosis: pathogenesis, differential diagnosis, and treatment","volume":"24","author":"M\u00f6ssner","year":"2026","journal-title":"J Dtsch Dermatol Ges"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1111\/jdv.17441","article-title":"A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS)","volume":"35","author":"Wilsmann-Theis","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40257-020-00503-5","article-title":"Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments","volume":"21","author":"Misiak-Galazka","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaad.2019.01.066","article-title":"Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study","volume":"80","author":"Mrowietz","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.2147\/IDR.S421299","article-title":"Refractory palmoplantar pustulosis successfully treated with JAK inhibitor tofacitinib: a case series","volume":"16","author":"Xu","year":"2023","journal-title":"Infect Drug Resist"},{"key":"B28","doi-asserted-by":"publisher","first-page":"112762","DOI":"10.1016\/j.intimp.2024.112762","article-title":"Janus kinase inhibitor tofacitinib successfully treated palmoplantar pustulosis after switching from secukinumab: a case report and review of the literature","volume":"139","author":"Fan","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"668","DOI":"10.25259\/IJDVL_884_2023","article-title":"A case of palmoplantar pustulosis with atopic dermatitis: baricitinib is a safe and effective treatment","volume":"90","author":"Li","year":"2024","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1111\/1346-8138.15860","article-title":"Remission of anti-tumor necrosis factor-\u03b1 antibody-induced palmoplantar pustulosis with the Janus kinase inhibitor baricitinib in a patient with rheumatoid arthritis","volume":"48","author":"Imafuku","year":"2021","journal-title":"J Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"508","DOI":"10.12144\/zgmfskin202407508","article-title":"Palmoplantar pustulosis successfully treated with abrocitinib: a case report","volume":"40","author":"Gao","year":"2024","journal-title":"China J Lepr Skin Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1913582\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:32:46Z","timestamp":1789533166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1913582\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":31,"alternative-id":["10.3389\/fmed.2026.1913582"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1913582","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1913582"}}